The m6A demethylation mediated by FTO relies on its m6A RNA demethylase activity to activate the PDGFRB/ERK signaling axis, playing an oncogenic role in NPM1-mutant AML and providing new epigenetic insights into the future treatment of this distinct aleukaemic entity [46]. This evidence concerns the gene FTO and acute myeloid leukemia.